FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385360897> ?p ?o ?g. }

• W4385360897 endingPage "315" @default.
• W4385360897 startingPage "309" @default.
• W4385360897 abstract "The aim of the work is to study the possibility of glucocorticoid (GC) discontinuation or their target dose achievement in patients (pts) with rheumatoid arthritis (RA) receiving conventional synthetic disease-modifying antirheumatic drugs (DMARDs). Materials and methods. 270 pts with RA (women – 86.6 %) aged 51.2 ± 0.71 years, with a disease duration of 50.20 ± 3.82 months were examined. Rheumatoid factor was found in 64.8 % of individuals, anti-cyclic citrullinated peptide (ACCP) antibodies – in 66.6 %. DMARD therapy included methotrexate (n = 91), leflunomide (n = 95), sulfasalazine (n = 51), hydroxychloroquine (n = 3) or its combination (n = 126). The SPSS (version 22.0) software was used for the statistical analysis. Results. During the 3-year study, GC was withdrawn in 33 % of pts in the period from 3 to 30 months (mostly in the first 6 moths). Among those who continued to take GC, the target dose (<7.5 mg/d) was achieved only in 32.6 % of pts. Among pts continuously receiving GC, compared with pts who discontinued GC therapy, there were significantly more women (89.5 % vs. 80.8 %), ACCP-positive pts (88.4 % vs. 55.0 %), with higher DAS-ESR values (5.29 ± 0.10 vs. 4.84 ± 0.15) and more pronounced structural changes on the SHS scale (43.40 ± 2.42 vs. 32.40 ± 2.71). According to the logistic regression analysis, female sex (OR 2.39), elderly pts (OR 1.02), ACCP-positivity (OR 3.73), disease activity by DAS-ESR (OR 1.19) and structural joint changes (OR 1.01) were significantly associated with the risk of continuing GC treatment. Only the initial dose of GC ≥7.5 mg/d was associated with the inability to reach the target dose of GC during the entire follow-up period (OR 6.32). Conclusions. Despite of the treatment with conventional synthetic DMARD, only a third of RA pts can withdraw GC, mostly in the first 6 months. For the pts who continue taking GC, the target dose can be achieved in 33 % of them. Independent predictors of the impossibility to withdraw GC are female sex, old age, ACCP-positivity, higher RA activity according to DAS-ESR and more pronounced joint destruction in early stages. An initial GC dose ≥7.5 mg/d is a negative prognostic factor in achieving the target dose." @default.
• W4385360897 created "2023-07-29" @default.
• W4385360897 creator A5056622887 @default.
• W4385360897 creator A5077323640 @default.
• W4385360897 date "2023-07-20" @default.
• W4385360897 modified "2023-09-26" @default.
• W4385360897 title "Is it possible to discontinue glucocorticoids in rheumatoid arthritis with the use of synthetic disease-modifying antirheumatic drugs?" @default.
• W4385360897 doi "https://doi.org/10.14739/2310-1210.2023.4.277503" @default.
• W4385360897 hasPublicationYear "2023" @default.
• W4385360897 type Work @default.
• W4385360897 citedByCount "0" @default.
• W4385360897 crossrefType "journal-article" @default.
• W4385360897 hasAuthorship W4385360897A5056622887 @default.
• W4385360897 hasAuthorship W4385360897A5077323640 @default.
• W4385360897 hasBestOaLocation W43853608971 @default.
• W4385360897 hasConcept C126322002 @default.
• W4385360897 hasConcept C198451711 @default.
• W4385360897 hasConcept C2775905006 @default.
• W4385360897 hasConcept C2776232647 @default.
• W4385360897 hasConcept C2776715498 @default.
• W4385360897 hasConcept C2777575956 @default.
• W4385360897 hasConcept C2778715236 @default.
• W4385360897 hasConcept C2779123688 @default.
• W4385360897 hasConcept C2779134260 @default.
• W4385360897 hasConcept C2779383735 @default.
• W4385360897 hasConcept C2780479503 @default.
• W4385360897 hasConcept C2781059491 @default.
• W4385360897 hasConcept C2908564923 @default.
• W4385360897 hasConcept C2909063479 @default.
• W4385360897 hasConcept C3008058167 @default.
• W4385360897 hasConcept C524204448 @default.
• W4385360897 hasConcept C71924100 @default.
• W4385360897 hasConcept C90924648 @default.
• W4385360897 hasConceptScore W4385360897C126322002 @default.
• W4385360897 hasConceptScore W4385360897C198451711 @default.
• W4385360897 hasConceptScore W4385360897C2775905006 @default.
• W4385360897 hasConceptScore W4385360897C2776232647 @default.
• W4385360897 hasConceptScore W4385360897C2776715498 @default.
• W4385360897 hasConceptScore W4385360897C2777575956 @default.
• W4385360897 hasConceptScore W4385360897C2778715236 @default.
• W4385360897 hasConceptScore W4385360897C2779123688 @default.
• W4385360897 hasConceptScore W4385360897C2779134260 @default.
• W4385360897 hasConceptScore W4385360897C2779383735 @default.
• W4385360897 hasConceptScore W4385360897C2780479503 @default.
• W4385360897 hasConceptScore W4385360897C2781059491 @default.
• W4385360897 hasConceptScore W4385360897C2908564923 @default.
• W4385360897 hasConceptScore W4385360897C2909063479 @default.
• W4385360897 hasConceptScore W4385360897C3008058167 @default.
• W4385360897 hasConceptScore W4385360897C524204448 @default.
• W4385360897 hasConceptScore W4385360897C71924100 @default.
• W4385360897 hasConceptScore W4385360897C90924648 @default.
• W4385360897 hasIssue "4" @default.
• W4385360897 hasLocation W43853608971 @default.
• W4385360897 hasOpenAccess W4385360897 @default.
• W4385360897 hasPrimaryLocation W43853608971 @default.
• W4385360897 hasRelatedWork W148160256 @default.
• W4385360897 hasRelatedWork W2044163764 @default.
• W4385360897 hasRelatedWork W2047026517 @default.
• W4385360897 hasRelatedWork W2092881439 @default.
• W4385360897 hasRelatedWork W2107754806 @default.
• W4385360897 hasRelatedWork W2314050163 @default.
• W4385360897 hasRelatedWork W2358266504 @default.
• W4385360897 hasRelatedWork W2373368171 @default.
• W4385360897 hasRelatedWork W2415558459 @default.
• W4385360897 hasRelatedWork W4226067500 @default.
• W4385360897 hasVolume "25" @default.
• W4385360897 isParatext "false" @default.
• W4385360897 isRetracted "false" @default.
• W4385360897 workType "article" @default.